Our R&D portfolio primarily reflects our scientific, technical and clinical competencies in vector-borne infectious diseases and in both bacterial and viral vaccines.
Clinical Pipeline
We want to make a difference in people’s lives by applying our innovative and pioneering science to address potential vaccine preventable diseases. Our pipeline includes vaccines for infectious diseases with major unmet needs in clinical development, where no vaccines are currently available.
Chikungunya – VLA1553
Chikungunya is a mosquito-borne viral infection spreading in the Americas and Europe caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus that has received several marketing approvals.
View MoreLyme Disease – VLA15 / LB6V
Lyme disease is the most common vector-borne illness in the Northern Hemisphere. VLA15/LB6V, partnered with Pfizer, is the vaccine candidate that has advanced the furthest along the clinical development timeline, with two pivotal Phase 3 trials completed. Its Marketing Authorization Application was accepted for review by EMA in August 2026 and regulatory decisions are expected in 2027.
View MoreShigella – S4V2
Shigellosis, caused by Shigella bacteria, is the second leading cause of fatal diarrheal disease worldwide. S4V2 is the world’s most clinically advanced tetravalent Shigella vaccine candidate.
View More